Monday 12 October 2026
Export all AMGN data to Excel Powerpack
Amgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.
414.87
7.43
+1.82%
Follow AMGN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
22.33 | 24.30 | 22.84 | 21.66 |
+8 more quarters Free account |
P/S ratio |
5.13 | 5.10 | 4.79 | 4.22 | |
P/FCF ratio |
20.07 | 23.28 | 22.97 | 13.67 | |
P/Operating CF |
48.86 | 86.80 | 109.85 | 32.41 | |
P/B ratio |
16.73 | 20.67 | 20.34 | 15.78 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
6.27 | 6.32 | 6.03 | 5.48 | |
EV/EBITDA |
14.48 | 14.83 | 14.34 | 12.85 | |
EV/Operating CF |
19.14 | 21.87 | 22.25 | 15.01 | |
EV/FCF |
24.52 | 28.82 | 28.90 | 17.74 | |
Quick Ratio |
0.95 | 0.85 | 0.73 | 0.82 | |
Current Ratio |
1.37 | 1.26 | 1.14 | 1.28 | |
Net Debt/EBITDA |
9.36 | 11.97 | 11.81 | 10.66 | |
Debt/Assets |
59.92% | 61.97% | 60.28% | 60.56% | |
Debt/Equity |
4.90 | 6.24 | 6.31 | 5.67 | |
Asset Turnover |
0.42 | 0.41 | 0.40 | 0.40 | |
Operating CF/Net income |
1.69 | 1.20 | 1.20 | 1.46 | |
Capex/Depreciation |
(0.46) | (0.64) | (0.57) | (0.26) | |
Interest Coverage |
5.22 | 4.06 | 4.17 | 3.69 | |
Research and Development Expense of Revenue |
18.58% | 19.95% | 21.71% | 19.88% | |
Selling, General and Administrative Expense of Revenue |
17.36% | 18.59% | 19.79% | 18.00% | |
Intangible Assets out of Total Assets |
0.41 | 0.43 | 0.45 | 0.46 | |
Share Based Compensation of Revenue |
1.64% | 0.87% | 1.27% | 1.33% | |
Graham Net Nets |
(0.25) | (0.27) | (0.30) | (0.35) | |
Graham Number |
88.88 | 74.46 | 72.03 | 72.40 | |
Earnings Yield |
4.48% | 4.12% | 4.38% | 4.62% | |
Free Cash Flow Yield |
4.98% | 4.30% | 4.35% | 7.31% | |
Revenue per Share |
18.62 | 15.96 | 18.34 | 17.76 | |
Operating CF per Share |
7.41 | 4.05 | 2.98 | 8.71 | |
Capex per Share |
(0.95) | (1.32) | (1.19) | (0.81) | |
Free Cash Flow per Share |
6.46 | 2.74 | 1.79 | 7.90 | |
Cash per Share |
25.91 | 22.29 | 16.97 | 17.56 | |
Shareholders Equity per Share |
21.64 | 17.02 | 16.09 | 17.88 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
21.64 | 17.02 | 16.09 | 17.88 | |
Free Cash Flow |
3,489.00 | 1,477.00 | 961.00 | 4,248.00 | |
Working Capital |
9,459.00 | 6,520.00 | 3,568.00 | 6,094.00 | |
Capital Expenditures |
(513.00) | (712.00) | (642.00) | (436.00) | |
Net Current Asset Value |
(48,990.00) | (51,839.00) | (52,871.00) | (52,637.00) | |
EV/EBIT |
20.90 | 22.26 | 24.40 | 22.72 | |
Capex to Sales |
0.05 | 0.08 | 0.07 | 0.05 | |
Price to Operating Income |
17.11 | 17.98 | 19.39 | 17.51 | |
| Other line items | |||||
Average Receivables |
9,464.00 | 8,635.00 | 8,176.00 | 7,903.50 | |
Average Payables |
2,937.50 | 2,670.50 | 2,137.50 | 2,492.50 | |
Average Inventory |
6,401.50 | 6,457.50 | 6,611.50 | 6,854.00 | |
Average Assets |
91,768.00 | 90,935.50 | 91,212.50 | 90,512.00 | |
Average Common Equity |
9,558.00 | 7,698.50 | 7,267.50 | 8,573.00 |
Columns are period end dates